- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
Détention brevets de la classe C07K 14/705
Brevets de cette classe: 15481
Historique des publications depuis 10 ans
|
923
|
1165
|
1288
|
1385
|
1566
|
1521
|
1427
|
1352
|
1149
|
411
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Regents of the University of California | 20590 |
338 |
| The Trustees of the University of Pennsylvania | 4403 |
329 |
| The Board of Trustees of the Leland Stanford Junior University | 6615 |
213 |
| Regeneron Pharmaceuticals, Inc. | 4643 |
198 |
| Memorial Sloan-Kettering Cancer Center | 2013 |
194 |
| Board of Regents, The University of Texas System | 6065 |
166 |
| Novartis AG | 10338 |
147 |
| Immatics Biotechnologies GmbH | 1118 |
140 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2980 |
138 |
| The General Hospital Corporation | 4840 |
98 |
| Dana-Farber Cancer Institute, Inc. | 2645 |
90 |
| Autolus Limited | 266 |
85 |
| City of Hope | 1020 |
82 |
| Alpine Immune Sciences, Inc. | 84 |
79 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 1010 |
77 |
| Baylor College of Medicine | 1000 |
76 |
| CRISPR Therapeutics AG | 365 |
72 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3333 |
71 |
| Lentigen Technology, Inc. | 106 |
71 |
| The Johns Hopkins University | 5844 |
70 |
| Autres propriétaires | 12747 |